![]() |
|
|
Product Details:
Payment & Shipping Terms:
|
Other Name: | Acomplia | CAS: | 168273-06-1 |
---|---|---|---|
MF: | C22H21Cl3N4O | MW: | 463.79 |
MP: | 230-240 ℃ | Appearance: | White Crystal Powder |
High Light: | Fat Cutter Steroids,Weight Loss Steroids |
99% Purity Rimonabant CAS 168273-06-1 White Raws for Obesity Treatment
Rimonabant (Acomplia) was studied for use in the treatment of obesity and related conditions.In clinical studies,Rimonabant was has been shown to improve a wide array of cardiometabolic risk factors as well as promoting sustained weight loss.Approximately half of the observed improvement in HDL-cholesterol, triglycerides and HbA1C (an indicator of blood sugar control) in patients who received Acomplia 20mg was beyond that expected from weight loss alone.
Quick Details:
Product name:Rimonabant,Acomplia
Synonyms: ACOMPLIA;RIMONABANT;RIMONABANT(ACOMPLIA,SR141716);5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-piperidinopyrazole-3-carboxamide;1H-Pyrazole-3-carboxamide, 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-1-piperidinyl-;5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide;A 281;Sr 141716
CAS:168273-06-1
Molecular Formula: C22H21Cl3N4O
Molecular Weight:463.79
Melting Point:230-240 ℃
Density:1.41g/cm3
Assay:99.5% min
Appearance: White crystal powder
COA:
Product name |
Rimonabant | |||
Production date |
May 3. 2016 | Shelf life |
May 2. 2018 | |
Standard adopted |
Enterprise standard | |||
Items of analysis |
Specification |
Results |
||
Assay by (HPLC) | 99%-101% | 99.43% | ||
Characters/appearance | White to off White powder | Complies | ||
Odor and taste | Odorless | Complies | ||
Identification | Positive reaction | Complies | ||
Mesh size/sieve analysis | 100% pass 80 mesh | Complies | ||
Loss on drying | 1% Max | 0.78% | ||
Water | ≤2.0% | 0.1% | ||
Residue on ignition | 01%Max | Complies | ||
Single impurity | 0.1% Max | Complies | ||
Malting point | 272.25 ºC | Complies | ||
Bolling point | 627 .69 ºC | Complies | ||
Refractive Index | N20O1.67 | Complies | ||
PH | 50-7.0 | 6.5 | ||
pK Values | pK. 11.31(Predicted). pK„ 3. 22 (Predicted) | Complies | ||
Solubility | Soluble in ethanol (-20 mg/ml). DMSO (25 mg/ml) | Complies | ||
Heavy Metals | NMT 10ppm | Complies | ||
Microbiological Control | 78cfu/g | 78cfu/g | ||
Total Plate Count | 1000 cfu/g Max | Negative | ||
Fungi | <100/g | Negative | ||
Salmonella | Negative | Negative | ||
Coll | negative | negative | ||
Conclusion |
Qualified |
How does Rimonabant work?
Rimonabant(Acomplia) acts by selectively blocking CB1 receptors found in the brain and in peripheral organs important in glucose and lipid (or fat) metabolism, including adipose tissue, the liver, gastrointestinal tract and muscle.
Acomplia switches off the same brain circuits that make people hungry when they smoke cannabis.
CB1 receptor blockade with Acomplia acts to decrease the overactivity of the endocannabinoid system (EC system).3,4 The EC system is a recently characterised physiological system that includes receptors such as the CB1 receptor and it has been shown to play an important role in regulating body weight and in controlling energy balance, as well as glucose and lipid (or fat) metabolism.
What is Rimonabant used for?
1) Rimonabant(Acomplia) was studied to be used complementary to diet and exercise to treat obese or overweight patients who suffer from type 2 diabetes and abnormal levels of fat in the blood.
2) Sanofi argued that Acomplia could also prevent the risk of cardiovascular disease.
Patients with large waist circumference (102 cm in men and 88 cm in women) were said to most benefit from taking the drug.
3) Smoking cessation.
Rimonabant may also be found to be effective in assisting some smokers to quit smoking. first, to use rimonabant directly to aid in smoking cessation; second, to help prevent weight gain in former smokers.
Dosage:
It is expected that the usual dose of rimonabant will be 20 mg once daily before breakfast. No dosage adjustment is recommended for the elderly, but this agent should be used with caution in patients older than 75 years of age.
Although rimonabant can be used in patients with mild hepatic impairment, caution is advised in patients with moderate impairment. This medication is not recommended for those with severe hepatic impairment.
Rimonabant may be used cautiously in patients with mild-to-moderate renal impairment, but it is not recommended for patients who are severely renally impaired.
There are no data supporting the use of rimonabant in pediatric populations.
Rimonabant should not be given to patients with a known hypersensitivity to the agent or any compound found in the tablet formulation.
The drug is contraindicated in lactat-ing women and is not recommended for use in women who are pregnant.
If you have any question pls feel free to contact me via:
Email: export@senwayer.com
Whats-app:+86-18186442580
Wickr me:yukis8888
We-chat:+86-18186442580
Tele-gram:+86-18186442580